In vitro transcription assay for T box antitermination system
View Patent ↗A method and assay system is provided for screening for antimicrobial agents that inhibit or otherwise disrupt the transcription of bacterial aminoacyl-tRNA synthetases, particularly those in Gram-positive bacteria. The method and assay utilizes purified RNA polymerase, isolated, for example, from either Bacillus subtilis or Escherichia coli , and a template DNA fragment which encodes glycyl-tRNA synthetase, containing the promoter and leader region of the B. subtilis glyQS gene, including the T-Box terminator/antiterminator. Incubation in the presence of nucleotide triphosphates results in synthesis of an RNA transcript initiating at the glyQS promoter and terminating at the leader region terminator. Read-through of the terminator, and synthesis of an extended transcript, is dependent on addition of purified glycyl-tRNA. The method and assay is dependent on the use of the specified tRNA species; non-specific tRNA fails to stimulate antitermination. The assay can be used to screen for inhibitors that specifically inhibit the T-box antitermination mechanism.
1. A method for screening substances which are potential inhibitors of expression of bacterial T-box regulated genes, comprising the steps of:
a) incubating one or more assay mixtures to produce a readthrough mRNA product, wherein the assay mixtures comprise: a template DNA that comprises: (i) a bacterial promoter, (ii) a glyQS leader, including a transcription start site, and (iii) a downstream polynucleotide of sufficient length for detection of a read-through mRNA product; divalent magnesium cations; nucleoside triphosphates; dinucleotides corresponding to and encoded by the transcription start site of the glyQS leader; bacterial RNA polymerase complex; and uncharged tRNA specific for a specifier sequence located in the glyQS leader; and
b) incubating a potential inhibitor substance with one or more assay mixtures to produce a readthrough mRNA product, wherein the assay mixtures comprise: a template DNA that comprises: (i) a bacterial promoter, (ii) a glyQS leader, including a transcription start site, and (iii) a downstream polynucleotide of sufficient length for detection of a read-through mRNA product; divalent magnesium cations; nucleoside triphosphates; dinucleotides corresponding to and encoded by the transcription start site of the glyQS leader; bacterial RNA polymerase complex; and uncharged tRNA specific for a specifier sequence located in the glyQS leader;
c) comparing the fraction of total mRNA products corresponding to the read-through mRNA product produced in step a) with the fraction of total mRNA products corresponding to the read-through mRNA product produced in step b)
wherein a lesser fraction of the read-through mRNA product produced in step b) in comparison with step a) indicates that said potential inhibitor substance inhibits transcriptional readthrough of said glyQS leader and therefore is an inhibitor of expression of bacterial T-box regulated genes.
2. The method recited in claim 1 wherein the divalent magnesium cation concentration is about 30 mM.
3. The method recited in claim 1 wherein the nucleoside triphosphates are selected from the group consisting of adenosine triphosphate, guanosine triphosphate, cytosine triphosphate, and uridine triphosphate, and any combination of one or more of these.
4. The method recited in claim 1 wherein the dinucleotides are selected from the group consisting of ApA, ApC, ApU, ApG, GpA, GpC, GpU, GpG, CpA, CpC, CpU, CpG, UpA, UpC, UpU, and UpG.
5. The method recited in claim 1 wherein the bacterial promoter is selected from the group consisting of a B. subtilis glyQS promoter and a B. subtilis rpsD promoter.
6. The method recited in claim 1 wherein the downstream polynucleotide of sufficient length for detection of a read-through mRNA product comprises a polynucleotide which is from about 30 to 150 nucleotide residues in length.
7. The method recited in claim 1 wherein the uncharged tRNA specific for a specifier sequence located in the glyQS leader is B. subtilis tRNA Gly .
8. The method recited in claim 1 wherein the RNA polymerase is purified from either B. subtilis or Escherichia coli.
9. The method recited in claim 1 wherein the glyQS leader comprises a variant glyQS leader sequence which is a variant of a wild-type glyQS leader from a Gram positive bacterial strain, wherein the variant glyQS leader sequence comprises modifications to one or both glyQS leader specifier and antiterminator sequences as compared to the wild-type glyQS leader.
10. The method recited in claim 1 wherein the uncharged tRNA specific for a specifier sequence located in the glyQS leader is a variant of a wild-type tRNA in which either or both wild-type anticodon sequence, or wild-type discriminator sequence, are altered to complement the glyQS leader sequence.
11. The method recited in claim 1 wherein the glyQS leader comprises a variant glyQS leader sequence which is a variant of a wild-type glyQS leader from a Gram positive bacterial strain, wherein the variant glyQS leader sequence comprises modifications to one or both wild-type glyQS leader specifier and antiterminator sequences, and wherein the uncharged tRNA specific for a specifier sequence located in the glyQS leader is a variant of a wild-type tRNA in which either or both wild-type anticodon sequence, or wild-type discriminator sequence are altered to complement the variant glyQS leader sequence.
12. The method recited in claim 1 wherein the assay mixtures comprises an in vitro halted-complex bacterial transcription assay systems.
13. A method for identifying inhibitors of expression of bacterial T-box regulated genes, comprising:
providing two or more in vitro halted-complex bacterial transcription assay systems which comprise a template DNA comprising: (i) a bacterial promoter, (ii) a polynucleotide comprising a portion of a leader from B. subtilis glyQS gene and including a transcription start site, and (iii) a downstream polynucleotide of sufficient length for detection of a read-through mRNA product; RNA polymerase, and uncharged B. subtilis tRNA Gly , wherein at least one or more of said assay systems comprises a test substance, and wherein at least one or more of said assay systems lacks a test substance, and comparing the fraction of total mRNA products corresponding to B. subtilis glyQS read-through mRNA produced in each of said assay systems, wherein a test substance is considered an inhibitor if it effects a lesser fraction of total mRNA products corresponding to the B. subtilis glyQS read-through mRNA produced in an assay system comprising said test substance as compared to an assay system lacking said test substance.
14. The method recited in claim 13 wherein the bacterial promoter is selected from the group consisting of a B. subtilis glyQS promoter and a B. subtilis rpsD promoter.
15. The method recited in claim 13 wherein the RNA polymerase is purified from either B. subtilis or Escherichia coli.
16. The method recited in claim 13 wherein the polynucleotide comprising a portion of the leader from the B. subtilis glyQS gene comprises a variant B. subtilis glyQS leader sequence comprising modifications to one or both B. subtilis glyQS leader specifier and antiterminator sequences as compared to the wild-type glyQS leader, and
wherein the uncharged B. subtilis tRNA Gly is a variant of a wild-type B. subtilis tRNA Gly in which either or both wild-type anticodon sequence and wild-type discriminator sequence are altered to complement the variant B. subtilis glyQS leader sequence.
17. A purified in vitro assay system for screening substances which are potential inhibitors of expression of bacterial T-box regulated genes, comprising:
a) one or more assay mixtures comprising: a template DNA that comprises: (i) a bacterial promoter, (ii) a glyQS leader, including a transcription start site, and (iii) a downstream polynucleotide of sufficient length for detection of a read-through mRNA product; divalent magnesium cations; nucleoside triphosphates; dinucleotides corresponding to and encoded by the transcription start site of the glyQS leader; bacterial RNA polymerase complex; and uncharged tRNA specific for a specifier sequence located in the glyQS leader; and
b) one or more assay mixtures comprising: a potential inhibitor substance; a template DNA that comprises: (i) a bacterial promoter, (ii) a glyQS leader, including a transcription start site, and (iii) a downstream polynucleotide of sufficient length for detection of a read-through mRNA product; divalent magnesium cations; nucleoside triphosphates; dinucleotides corresponding to and encoded by the transcription start site of the glyQS leader; bacterial RNA polymerase complex; and uncharged tRNA specific for a specifier sequence located in the glyQS leader.
18. The assay system recited in claim 17 wherein the divalent magnesium cation concentration is about 30 mM.
19. The assay system recited in claim 17 wherein the nucleoside triphosphates are selected from the group consisting of adenosine triphosphate, guanosine triphosphate, cytosine triphosphate, and uridine triphosphate, and any combination of one or more of these.
20. The assay system recited in claim 17 wherein the dinucleotides are selected from the group consisting of ApA, ApC, ApU, ApG, GpA, GpC, GpU, GpG, CpA, CpC, CpU, CpG, UpA, UpC, UpU, and UpG.
21. The assay system recited in claim 17 wherein the bacterial promoter is selected from the group consisting of a B. subtilis glyQS promoter and a B. subtilis rpsD promoter.
22. The assay system recited in claim 17 wherein the downstream polynucleotide of sufficient length for detection of a read-through mRNA product comprises a polynucleotide which is from about 30 to 150 nucleotide residues in length.
23. The assay system recited in claim 17 wherein the uncharged tRNA specific for a specifier sequence located in the glyQS leader is B. subtilis tRNA Gly .
24. The assay system recited in claim 17 wherein the RNA polymerase is purified from either B. subtilis or Escherichia coli.
25. The assay system recited in claim 17 wherein the glyQS leader comprises a variant glyQS leader sequence which is a variant of a wild-type glyQS leader from a Gram positive bacterial strain, wherein the variant glyQS leader sequence comprises modifications to one or both glyQS leader specifier and antiterminator sequences as compared to the wild-type glyQS leader.
26. The assay system recited in claim 17 wherein the uncharged tRNA specific for a specifier located in the glyQS leader is a variant of a wild-type tRNA in which either or both wild-type anticodon sequence, or wild-type discriminator sequence, are altered to complement the glyQS leader sequence.
27. The assay system recited in claim 17 wherein the leader comprises a variant glyQS leader sequence which is a variant of a wild-type glyQS leader from a Gram positive bacterial strain, wherein the variant glyQS leader sequence comprises modifications to one or both glyQS leader specifier antiterminator sequences as compared to the wild-type glyQS leader, and wherein the uncharged tRNA specific for a specifier sequence located in the glyQS leader is a variant of a wild-type tRNA in which either or both wild-type anticodon sequence, or wild-type discriminator sequence are altered to complement the variant glyQS leader sequence.
28. The assay system recited in claim 17 wherein the assay comprises an in vitro halted-complex bacterial transcription assay system.
29. A purified in vitro assay system for identifying inhibitors of expression of bacterial T-box regulated genes, comprising:
two or more in vitro halted-complex bacterial transcription assay systems which comprise a template DNA comprising: (i) a bacterial promoter, (ii) a polynucleotide comprising a portion of a leader from B. subtilis glyQS gene, including a transcription start site, and (iii) a downstream polynucleotide of sufficient length for detection of a read-through mRNA product; RNA polymerase, and uncharged B. subtilis tRNA Gly , wherein at least one or more of said assay systems comprises a test substance, and wherein at least one or more of said assay systems lacks a test substance.
30. The assay system recited in claim 29 wherein the bacterial promoter is selected from the group consisting of a B. subtilis glyQS promoter and a B. subtilis rpsD promoter.
31. The assay system recited in claim 29 wherein the RNA polymerase is purified from either B. subtilis or Escherichia coli.
32. The assay system recited in claim 29 wherein the polynucleotide comprising a portion of the leader from the B. subtilis glyQS gene comprises a variant B. subtilis glyQS leader sequence comprising modifications to one or both B. subtilis glyQS leader specifier and antiterminator sequences as compared to the wild-type glyQS leader, and
wherein the uncharged B. subtilis tRNA Gly is a variant of a wild-type B. subtilis tRNA Gly in which either or both wild-type anticodon sequence and wild-type discriminator sequence are altered to complement the variant B. subtilis glyQS leader sequence.